Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML

Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML

Tyrosine kinase inhibitor (TKI) combination is expected to increase in the era of precision medicine. TKI combination may be required to treat double primary cancers, each having a targetable gene, or to treat a single malignancy with multiple targetable genes. Here, we demonstrate the first report...

Full description

Saved in:
Bibliographic Details
Main Authors: Kousuke Watanabe, Hidenori Kage, Saki Nagoshi, Kazuhiro Toyama, Yoshiyuki Ohno, Aya Shinozaki-Ushiku, Kumi Nakazaki, Hiroshi Suzuki, Mineo Kurokawa, Takahide Nagase
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Case Reports in Oncological Medicine
Online Access:http://dx.doi.org/10.1155/2020/4201727
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items